tiprankstipranks
Advertisement
Advertisement

TSE:HLS Stock Latest News

HLS Therapeutics: Near-Term Softness Masking NILEMDO-Driven Growth Upside, Supporting Buy Rating
RatingsHLS Therapeutics: Near-Term Softness Masking NILEMDO-Driven Growth Upside, Supporting Buy Rating
26d ago
HLS Therapeutics price target lowered to C$4.45 from C$4.75 at Stifel
PremiumThe Fly
HLS Therapeutics price target lowered to C$4.45 from C$4.75 at Stifel
1M ago
HLS Therapeutics Lifts Profitability, Cuts Debt as It Expands Cardiovascular Portfolio
PremiumCompany Announcements
HLS Therapeutics Lifts Profitability, Cuts Debt as It Expands Cardiovascular Portfolio
1M ago
Is HLS a Buy, Before Earnings?
PremiumPre-Earnings
Is HLS a Buy, Before Earnings?
1M ago
HLS Therapeutics launches NILEMDO in Canada to tackle unmet cholesterol treatment needs
PremiumCompany Announcements
HLS Therapeutics launches NILEMDO in Canada to tackle unmet cholesterol treatment needs
1M ago
HLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs
PremiumCompany AnnouncementsHLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs
1M ago
HLS Therapeutics Sets March 12 Date for Fiscal 2025 Results and Investor Call
Premium
Company Announcements
HLS Therapeutics Sets March 12 Date for Fiscal 2025 Results and Investor Call
2M ago
HLS Therapeutics price target raised to C$4.75 from C$4 at Stifel
Premium
The Fly
HLS Therapeutics price target raised to C$4.75 from C$4 at Stifel
4M ago
Positive Outlook for HLS Therapeutics Inc. Amid Regulatory Developments and Product Approvals
PremiumRatings
Positive Outlook for HLS Therapeutics Inc. Amid Regulatory Developments and Product Approvals
5M ago
HLS Therapeutics Gains Health Canada Approval for NILEMDO®
PremiumCompany Announcements
HLS Therapeutics Gains Health Canada Approval for NILEMDO®
5M ago
HLS Therapeutics Inc.: Strategic Resilience and Growth Potential Amidst Market Challenges
PremiumRatings
HLS Therapeutics Inc.: Strategic Resilience and Growth Potential Amidst Market Challenges
5M ago
HLS Therapeutics Reports Mixed Earnings Amid Growth Challenges
PremiumCompany Announcements
HLS Therapeutics Reports Mixed Earnings Amid Growth Challenges
5M ago
HLS Therapeutics Reports Strong Q3 2025 Results and Prepares for New Product Launch
PremiumCompany AnnouncementsHLS Therapeutics Reports Strong Q3 2025 Results and Prepares for New Product Launch
5M ago
HLS Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
HLS Upcoming Earnings Report: What to Expect?
5M ago
HLS Therapeutics to Announce Q3 2025 Financial Results
Premium
Company Announcements
HLS Therapeutics to Announce Q3 2025 Financial Results
5M ago
HLS Therapeutics and Amarin Highlight Cardiovascular Advances at Canadian Congress
PremiumCompany Announcements
HLS Therapeutics and Amarin Highlight Cardiovascular Advances at Canadian Congress
6M ago
HLS Therapeutics Secures New Credit Agreement for Financial Flexibility
PremiumCompany Announcements
HLS Therapeutics Secures New Credit Agreement for Financial Flexibility
8M ago
HLS Therapeutics Inc: Strong Q2 Performance and Optimistic Outlook Justify Buy Rating
PremiumRatings
HLS Therapeutics Inc: Strong Q2 Performance and Optimistic Outlook Justify Buy Rating
8M ago
HLS Therapeutics Reports Strong Q2 2025 Financials and Strategic Expansion
PremiumCompany Announcements
HLS Therapeutics Reports Strong Q2 2025 Financials and Strategic Expansion
8M ago
HLS Earnings this Week: How Will it Perform?
PremiumPre-EarningsHLS Earnings this Week: How Will it Perform?
8M ago
HLS Therapeutics to Announce Q2 2025 Financial Results
Premium
Company Announcements
HLS Therapeutics to Announce Q2 2025 Financial Results
9M ago
HLS Therapeutics Secures Nova Scotia Reimbursement for Vascepa
Premium
Company Announcements
HLS Therapeutics Secures Nova Scotia Reimbursement for Vascepa
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >